Compare SNGX & YMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | YMAT |
|---|---|---|
| Founded | 1987 | 1970 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Recreational Games/Products/Toys |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 8.1M |
| IPO Year | 2006 | 2021 |
| Metric | SNGX | YMAT |
|---|---|---|
| Price | $0.34 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $1.38 | N/A |
| AVG Volume (30 Days) | 102.4K | ★ 6.1M |
| Earning Date | 11-06-2026 | 10-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.32 | $0.24 |
| 52 Week High | $3.39 | $4.49 |
| Indicator | SNGX | YMAT |
|---|---|---|
| Relative Strength Index (RSI) | 35.83 | 38.62 |
| Support Level | $0.32 | $0.32 |
| Resistance Level | $0.82 | $2.27 |
| Average True Range (ATR) | 0.02 | 0.41 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 26.22 | 8.46 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
J-Star Holding Co Ltd is engaged in the research, development, and manufacturing of carbon fiber for a wide variety-of-products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products. The company has five segments: Bicycle frame, Racket, Crank, Service provision, and Others. The majority of its revenue is generated from the Bicycle frame segment. Geographically, the company operates in Taiwan, China, and other regions.